EA201590349A1 - Режимы лечения - Google Patents

Режимы лечения

Info

Publication number
EA201590349A1
EA201590349A1 EA201590349A EA201590349A EA201590349A1 EA 201590349 A1 EA201590349 A1 EA 201590349A1 EA 201590349 A EA201590349 A EA 201590349A EA 201590349 A EA201590349 A EA 201590349A EA 201590349 A1 EA201590349 A1 EA 201590349A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment modes
treatment
hsdd
disorders
humans
Prior art date
Application number
EA201590349A
Other languages
English (en)
Russian (ru)
Inventor
Николас Г. Ситчон
Роберт И. Пайк
Джон Ф. Кауфманн
Original Assignee
С1 Биофарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by С1 Биофарма, Инк. filed Critical С1 Биофарма, Инк.
Publication of EA201590349A1 publication Critical patent/EA201590349A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201590349A 2012-08-06 2013-08-06 Режимы лечения EA201590349A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679999P 2012-08-06 2012-08-06
PCT/US2013/053843 WO2014025814A1 (en) 2012-08-06 2013-08-06 Treatment regimens

Publications (1)

Publication Number Publication Date
EA201590349A1 true EA201590349A1 (ru) 2015-07-30

Family

ID=50068530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590349A EA201590349A1 (ru) 2012-08-06 2013-08-06 Режимы лечения

Country Status (15)

Country Link
US (1) US9517254B2 (enExample)
EP (1) EP2879680A4 (enExample)
JP (2) JP2015524474A (enExample)
KR (4) KR20230136142A (enExample)
CN (2) CN106924259A (enExample)
AU (2) AU2013299725A1 (enExample)
BR (1) BR112015002687A2 (enExample)
CA (1) CA2881388A1 (enExample)
EA (1) EA201590349A1 (enExample)
HK (2) HK1211239A1 (enExample)
IL (1) IL237150B (enExample)
MX (1) MX2015001695A (enExample)
SG (3) SG10201709967YA (enExample)
WO (1) WO2014025814A1 (enExample)
ZA (1) ZA201501562B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170142797A (ko) * 2016-06-17 2017-12-28 에스원 바이오파머, 인크. 부프로피온 및 트라조돈 조합 치료를 이용한 여성의 성욕 감퇴 장애（ｈｓｄｄ）의 치료 방법
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2025042884A2 (en) * 2023-08-21 2025-02-27 Kuleon Llc Serotonin receptor modulators for the treatment of addictions and overdoses
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2025245102A2 (en) * 2024-05-21 2025-11-27 S1 Biopharma, Inc. Methods and compositions for treating sexual disorder, weight loss, weight maintenance, well-being, and self-esteem

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687771A (en) 1985-11-01 1987-08-18 Bristol-Myers Company Method for treatment of male impotence
DE4321965A1 (de) 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2002322085A (ja) 2001-04-26 2002-11-08 Kazuhito Tomizawa 知的機能障害治療剤
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ATE477811T1 (de) * 2002-10-03 2010-09-15 Neuropharmacology Services Llc Oxytocin zur behandlung von autismus und asperger-syndrom
WO2004078147A2 (en) 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
CN1946404A (zh) 2004-04-22 2007-04-11 贝林格尔·英格海姆国际有限公司 用于治疗性功能疾病ⅱ的新颖药物组合物
KR20070014184A (ko) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20060004076A1 (en) 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
WO2006096435A1 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
WO2008075162A2 (en) 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
WO2009016488A2 (en) * 2007-08-02 2009-02-05 Compugen, Ltd. Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
US20100048630A1 (en) * 2008-08-21 2010-02-25 Pradeep Banerjee Methods for treating cns disorders
MX353752B (es) * 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
WO2011146726A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders
WO2012016229A2 (en) 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose
EA201391459A1 (ru) 2011-04-04 2014-03-31 С1 Биофарма, Инк. Режимы лечения

Also Published As

Publication number Publication date
EP2879680A1 (en) 2015-06-10
KR20250041078A (ko) 2025-03-25
US20150150946A1 (en) 2015-06-04
US9517254B2 (en) 2016-12-13
SG10201908587PA (en) 2019-10-30
ZA201501562B (en) 2017-11-29
EP2879680A4 (en) 2016-06-01
IL237150A0 (en) 2015-04-30
HK1211239A1 (en) 2016-05-20
AU2018205121A1 (en) 2018-07-26
SG10201709967YA (en) 2018-01-30
WO2014025814A1 (en) 2014-02-13
CN104884060A (zh) 2015-09-02
HK1214505A1 (zh) 2016-07-29
KR20200128437A (ko) 2020-11-12
IL237150B (en) 2018-07-31
KR20150063039A (ko) 2015-06-08
CN106924259A (zh) 2017-07-07
JP2018150357A (ja) 2018-09-27
KR20230136142A (ko) 2023-09-26
BR112015002687A2 (pt) 2019-12-17
AU2013299725A1 (en) 2015-03-26
JP2015524474A (ja) 2015-08-24
MX2015001695A (es) 2015-09-28
SG11201500919PA (en) 2015-04-29
CA2881388A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX384023B (es) Tratamiento de mielosupresion.
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201790963A1 (ru) Противовирусные соединения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
TR201815173T4 (tr) Peptit bileşimleri.
JO3516B1 (ar) مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
EA201492280A1 (ru) Стабильный состав пексиганана